(BLUE) stock downgraded by Bank of America and J.P. Morgan after the company's Q3 2024 results. Read more here.

Scotland's finest corporate financiers, accountants, bankers, funders, lawyers and mergers and acquisitions professionals ...

Investing.com -- Following Donald Trump's recent election victory, JPMorgan (NYSE:JPM)'s quantitative analysts anticipate ...

JPMorgan Chase & Co. Chief Executive Officer Jamie Dimon said companies will look harder at acquisitions in the wake of the ...

consultancy in digital change and risk management at JP Morgan Chase, and operational enhancement at Amazon. In this ...

In a recent interview, J.P. Morgan CEO Jamie Dimon expressed growing concerns about what’s happening in the world today, ...

As more wealthy empty nesters stick to the North Shore rather than move to the Loop, the banking giant says they're looking ...

In celebration of its 100th year as an institution open to the public, the Morgan Library and Museum has launched the ...

On Tuesday, bluebird bio Inc (BLUE) stock saw a decline, ending the day at $0.39 which represents a decrease of $-0.02 or -4.88% from the prior close of $0.41. The stock opened at $0.4 and touched a ...

Belite Bio, Inc. ( NASDAQ: BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief ...

JP Morgan has recently reduced bluebird bio Inc (BLUE) stock to Neutral rating, as announced on August 15, 2024, according to Finviz. Earlier, on December 11, 2023, HSBC Securities had reduced the ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) yesterday and set a price ...